A selective antagonist of mineralocorticoid receptor eplerenone in cardiology practice

被引：0
|
作者：
Gegenava, B. B. [1 ]
Drapkina, O. M. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2015年 / 11卷 / 02期
关键词：
aldosterone; heart failure; atrial fibrillation; chronic renal failure; albuminuria; eplerenone; spironolactone; gynecomastia;
D O I：
10.20996/1819-6446-2015-11-2-177-181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
引用
收藏
页码：177 / 181
页数：5
相关论文
共 50 条
  • [21] Mineralocorticoid receptor antagonist eplerenone alleviates the reduction and dysfunction of endothelial progenitor cells in hypertensive patients
    Wang, Huanhuan
    Zhu, Aoshuang
    Wang, Xin
    Zang, Xuan
    Huang, Changgen
    Zhao, Jianzhong
    Ding, Zhijian
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (08): : 7979 - 7986
  • [22] Molecular basis of the antagonism of the mineralocorticoid receptor by eplerenone
    Rogerson, FM
    Yao, YZ
    Smith, BJ
    Fuller, PJ
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (5-6) : A27 - A28
  • [23] Eplerenone, a new selective mineralocorticoid receptor antagonist, inhibits platelet adhesion and attenuates endothelial damage in arterial thrombosis model in diabetic rats
    Chabielska, Ewa
    Bycul, Urszula
    Zakrzeska, Agnieszka
    Szoka, Piotr
    Kisiel, Wioleta
    Kasacka, Irena
    THROMBOSIS RESEARCH, 2012, 130 : S136 - S137
  • [24] Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone
    Hu, X
    Li, SZ
    McMahon, EG
    Lala, DS
    Rudolph, AE
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (08) : 709 - 718
  • [25] Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
    Savoia, Carmine
    Touyz, Rhian M.
    Schiffrin, Ernesto L.
    HYPERTENSION, 2007, 50 (04) : E82 - E82
  • [26] The selective mineralocorticoid receptor antagonist eplerenone improves endothelial function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus
    Schaefer, A.
    Vogt, C.
    Flierl, U.
    Ertl, G.
    Bauersachs, J.
    EUROPEAN HEART JOURNAL, 2008, 29 : 486 - 487
  • [27] Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
    Savoia, C.
    Touyz, R. M.
    Schiffrin, E. L.
    CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 : 86C - 86C
  • [28] Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
    Savoia, Carmine
    Touyz, Rhian M.
    Amiri, Farhad
    Schiffrin, Ernesto L.
    HYPERTENSION, 2008, 51 (02) : 432 - 439
  • [29] Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
    Palanisamy, Srikanth
    Hernandez, Mario Funes
    Chang, Tara, I
    Mahaffey, Kenneth W.
    CARDIOLOGY AND THERAPY, 2022, 11 (03) : 337 - 354
  • [30] Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
    Srikanth Palanisamy
    Mario Funes Hernandez
    Tara I. Chang
    Kenneth W. Mahaffey
    Cardiology and Therapy, 2022, 11 : 337 - 354
12345